TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Well Being of Obstetric Patients on Minimal Blood Transfusions
Brief Summary: Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.


Options:
A: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy
B: Arm Label: Bair hugger forced air warming therapy; Type: EXPERIMENTAL; Interventions: Device: Bair Hugger forced air warming system | Arm Label: conventional warming care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bair Hugger forced air warming system; Assigned to Arm(s): Bair hugger forced air warming therapy
C: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
D: Arm Label: "liberal" transfusion triggers; Type: EXPERIMENTAL; Interventions: Other: red blood cell transfusion | Arm Label: "restrictive" transfusion triggers; Type: ACTIVE_COMPARATOR; Interventions: Other: red blood cell transfusion | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "liberal" transfusion triggers | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "restrictive" transfusion triggers

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Well Being of Obstetric Patients on Minimal Blood Transfusions
Brief Summary: Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.


Options:
A: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
B: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
C: Arm Label: Restrictive Red blood cell Transfusion; Type: EXPERIMENTAL; Interventions: Other: Red blood cell Transfusion | Arm Label: Liberal Red blood Cell Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell Transfusion | Intervention Type: OTHER; Name: Red blood cell Transfusion; Assigned to Arm(s): Liberal Red blood Cell Transfusion, Restrictive Red blood cell Transfusion
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion with Red Blood Cells, Biological: 1 unit of donated red blood cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1 unit of donated red blood cells | Intervention Type: PROCEDURE; Name: Transfusion with Red Blood Cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Theories About Myopia Progression (STAMP)
Brief Summary: At this time, we do not know what causes a child to become more nearsighted (myopic). STAMP will help us better understand nearsightedness in children. Children will be randomly chosen to wear regular glasses (single vision lenses) or no-line bifocal glasses (progressive addition lenses) for the first year of the study. All children will wear regular glasses for the second year of the study. STAMP will compare how the eye changes shape in the two groups to help us understand why children become nearsighted. The two theories of myopia progression that are being evaluated are based on different factors. One theory is based on environmental factors such as extended near work while the other theory is based on genetically coded factors.


Options:
A: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses
B: Arm Label: omafilcon A; Type: EXPERIMENTAL; Interventions: Device: omafilcon A | Arm Label: Spectacle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: omafilcon A; Assigned to Arm(s): omafilcon A | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle Group
C: Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses
D: Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Theories About Myopia Progression (STAMP)
Brief Summary: At this time, we do not know what causes a child to become more nearsighted (myopic). STAMP will help us better understand nearsightedness in children. Children will be randomly chosen to wear regular glasses (single vision lenses) or no-line bifocal glasses (progressive addition lenses) for the first year of the study. All children will wear regular glasses for the second year of the study. STAMP will compare how the eye changes shape in the two groups to help us understand why children become nearsighted. The two theories of myopia progression that are being evaluated are based on different factors. One theory is based on environmental factors such as extended near work while the other theory is based on genetically coded factors.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Outdoor activity; Type: EXPERIMENTAL; Interventions: Behavioral: Outdoor activity | Intervention Type: BEHAVIORAL; Name: Outdoor activity; Assigned to Arm(s): Outdoor activity
B: Arm Label: auricular acupoint stimulation; Type: EXPERIMENTAL; Interventions: Drug: Atropine, Device: auricular acupoint stimulation | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, auricular acupoint stimulation | Intervention Type: DEVICE; Name: auricular acupoint stimulation; Assigned to Arm(s): auricular acupoint stimulation
C: Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses
D: Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.
Brief Summary: This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.


Options:
A: Arm Label: pramipexole; Type: EXPERIMENTAL; Interventions: Drug: Pramipexole | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Pramipexole; Assigned to Arm(s): pramipexole | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pardaprunox | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pramipexole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pardaprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pramipexole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pardoprunox | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pardoprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: 1mg rasagiline; Type: EXPERIMENTAL; Interventions: Drug: Rasagiline Mesylate | Arm Label: 2mg rasagiline; Type: EXPERIMENTAL; Interventions: Drug: Rasagiline Mesylate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rasagiline Mesylate; Assigned to Arm(s): 1mg rasagiline | Intervention Type: DRUG; Name: Rasagiline Mesylate; Assigned to Arm(s): 2mg rasagiline | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.
Brief Summary: This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: health education | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene, Device: face masks | Intervention Type: BEHAVIORAL; Name: hand hygiene; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: face masks; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pardaprunox | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pramipexole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pardaprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pramipexole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: amantadine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oseltamivir phosphate; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pardoprunox | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pardoprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Active Surveillance Study of Women Taking Oral Contraceptives (INAS OC)
Brief Summary: The study compares the short- and long-term risks of a 24-day regimen of a drospirenone-containing oral contraceptive with the risks of established oral contraceptives in a study population that is representative for the actual users of the individual preparations.


Options:
A: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
B: Arm Label: Normal Weight group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Arm Label: Obese group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Intervention Type: DRUG; Name: Low dose formulation; Assigned to Arm(s): Normal Weight group, Obese group | Intervention Type: DRUG; Name: High dose formulation; Assigned to Arm(s): Normal Weight group, Obese group
C: Arm Label: All participants; Type: OTHER; Interventions: Drug: All participants (Aviane) | Arm Label: Aviane and Portia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Portia | Arm Label: Aviane & Aviane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aviane | Intervention Type: DRUG; Name: All participants (Aviane); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: Portia; Assigned to Arm(s): Aviane and Portia | Intervention Type: DRUG; Name: Aviane; Assigned to Arm(s): Aviane & Aviane
D: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RENEW Intervention for Elderly Cancer Survivors
Brief Summary: RATIONALE: Exercise may help improve mobility and relieve fatigue and/or weakness in cancer survivors. It is not yet known whether exercise is more effective than standard therapy in improving mobility and reducing fatigue and/or weakness in older cancer survivors.

PURPOSE: This randomized clinical trial is studying exercise to see how well it works compared to standard therapy in improving mobility and reducing fatigue and/or weakness in older cancer survivors.


Options:
A: Intervention Type: DEVICE; Name: Pedometer; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Exercise guidebook; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: complementary or alternative medicine procedure; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fatigue assessment and management; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: physical therapy; Assigned to Arm(s): N/A
D: Arm Label: Physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RENEW Intervention for Elderly Cancer Survivors
Brief Summary: RATIONALE: Exercise may help improve mobility and relieve fatigue and/or weakness in cancer survivors. It is not yet known whether exercise is more effective than standard therapy in improving mobility and reducing fatigue and/or weakness in older cancer survivors.

PURPOSE: This randomized clinical trial is studying exercise to see how well it works compared to standard therapy in improving mobility and reducing fatigue and/or weakness in older cancer survivors.


Options:
A: Arm Label: High intensity; Type: EXPERIMENTAL; Interventions: Behavioral: high intensity exercise | Arm Label: Low/Medium intensity; Type: EXPERIMENTAL; Interventions: Behavioral: low/medium intensity exercise | Arm Label: High Intensity with BM; Type: EXPERIMENTAL; Interventions: Behavioral: high intensity exercise, Behavioral: Behavioral medicine strategies | Arm Label: Low/Medium intensity with BM; Type: EXPERIMENTAL; Interventions: Behavioral: low/medium intensity exercise, Behavioral: Behavioral medicine strategies | Intervention Type: BEHAVIORAL; Name: high intensity exercise; Assigned to Arm(s): High Intensity with BM, High intensity | Intervention Type: BEHAVIORAL; Name: low/medium intensity exercise; Assigned to Arm(s): Low/Medium intensity, Low/Medium intensity with BM | Intervention Type: BEHAVIORAL; Name: Behavioral medicine strategies; Assigned to Arm(s): High Intensity with BM, Low/Medium intensity with BM
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Psychosocial rehabilitation course | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychosocial rehabilitation course; Assigned to Arm(s): Intervention group
C: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: complementary or alternative medicine procedure; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fatigue assessment and management; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: physical therapy; Assigned to Arm(s): N/A
D: Arm Label: Hatha yoga; Type: EXPERIMENTAL; Interventions: Behavioral: Hatha yoga | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Hatha yoga; Assigned to Arm(s): Hatha yoga

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Study: A Randomized, Double-blinded Trial of Clonidine for Reducing Cardiac Morbidity and Mortality Following Non-cardiac Surgery.
Brief Summary: In Canada 1 patient in 200 dies within 30 days of an operation. More than half of these deaths are the direct result of a heart related complication. This cause of death happens 4 times more often than in the same people who do not have an operation. We do not have an effective way to stop these heart attacks. Stress causes the heart rate and the blood pressure to go up which causes the heart to work harder and may be the reason for some heart attacks. One group of drugs that stops the heart from working harder and decrease the number of heart related complications are BETA-BLOCKERS. We wish to add another drug, which has been shown to reduce heart rate and blood pressure, will reduce the number of heart attacks after an operation. CLONIDINE has been shown to reduce heart attacks after operations. Since we know it is not a good idea to stop beta-blockers we want to see if giving clonidine as well as a beta-blocker is safe and has the desired effect of decreasing the number of heart attacks. We want to find out how good the combination of these two drugs are at decreasing the number of heart attacks.

Hypothesis: The addition of clonidine to chronic b-blockade will reduce mortality and cardiac morbidity among intermediate-to-high risk patients undergoing non-cardiac surgery.


Options:
A: N/A
B: Intervention Type: DRUG; Name: clonidine hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Dex group; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine hydrochloride for injection | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride for injection | Intervention Type: DRUG; Name: dexmedetomidine hydrochloride for injection; Assigned to Arm(s): Dex group | Intervention Type: DRUG; Name: 0.9% sodium chloride for injection; Assigned to Arm(s): Placebo group

Answer: B